Post ASCO 2026 Updates is an expert led session focused on high level clinical updates emerging from the 2026 American Society of Clinical Oncology Annual Meeting. The discussion will be organized by disease category and clinical domain, with each faculty member reviewing recent data through the lens of their subspecialty expertise and its potential relevance to patient care. Plasma cell disorders and monoclonal gammopathies will be discussed by Adeel Khan, MD, Assistant Professor of Internal Medicine in the Division of Hematology and Oncology at UT Southwestern Medical Center. This portion of the session will broadly address clinical updates relevant to multiple myeloma, amyloidosis, and related precursor states, with emphasis on evolving approaches to disease assessment and management. Bone marrow failure syndromes and clonal cytopenias will be covered by Taha Bat, MD, Assistant Professor of Internal Medicine at UT Southwestern. His segment will focus on recent clinical developments applicable to marrow based disorders, highlighting how emerging evidence may inform diagnostic evaluation and therapeutic decision making in patients with complex cytopenias. Leukemia related updates will be presented by Moaath Mustafa Ali, MD, MPH, hematologist and medical oncologist at Cleveland Clinic specializing in leukemia and related hematologic malignancies. He is board certified in internal medicine, hematology, and medical oncology. With training in clinical medicine and public health, his work focuses on leukemia care, transplantation outcomes, and clinical research. His segment will review selected clinical developments across acute and chronic leukemias, with attention to evolving therapeutic strategies and their potential implications for patient care. Lymphoma and cellular therapy related updates will be presented by Elif Yilmaz, MD, Assistant Professor of Internal Medicine at UT Southwestern. This section will review selected clinical updates relevant to indolent and aggressive lymphomas, with attention to evolving treatment strategies and integration of novel therapies. Together, these categorical discussions will provide a concise overview of Post ASCO 2026 clinical updates across major hematologic disease areas, emphasizing interpretation of new evidence within real world clinical practice.

Keith McCrae, MD is a Professor of Molecular Medicine at the Cleveland Clinic Lerner College of Medicine and serves as the Director of Classical Hematology at the Taussig Cancer Institute. He also holds the position of Director of Physician-Scientist Development at the Cleveland Clinic Lerner Research Institute. Keith McCrae, MD earned his medical degree from Duke University School of Medicine and completed his residency at Duke University Medical Center. He is board-certified in Internal Medicine, Medical Oncology, and Hematology. Keith McCrae, MD's research focuses on vascular biology, particularly in the context of thrombosis and bleeding disorders. His laboratory investigates the mechanisms underlying conditions such as antiphospholipid syndrome and cancer-associated thrombosis. Notably, he led a multicenter study assessing the efficacy of pomalidomide in treating hereditary hemorrhagic telangiectasia (HHT), a rare vascular disorder. This study, published in the New England Journal of Medicine, demonstrated that pomalidomide effectively reduced bleeding episodes in HHT patients, marking a significant advancement in the treatment of this condition. In addition to his research, Keith McCrae, MD is an active educator and has received several accolades for his contributions to medical education. He has authored numerous publications in peer-reviewed journals and serves as the Editor-in-Chief of Blood Vessels, Thrombosis and Hemostasis, an American Society of Hematology publication. His work continues to influence the understanding and treatment of vascular disorders, bridging the gap between basic science and clinical application.

Adam Cuker, MD is a Professor of Medicine and Pathology & Laboratory Medicine at the University of Pennsylvania. He serves as the Section Chief of Hematology and Clinical Director of the Penn Blood Disorders Center. Additionally, he is the Director of the Penn Comprehensive Hemophilia and Thrombosis Program and Assistant Director of the Penn Specialized Coagulation Laboratory. Adam Cuker, MD earned his MD from Yale University and completed his internship and residency in internal medicine at Brigham and Women's Hospital. He pursued a fellowship in hematology/oncology at the Hospital of the University of Pennsylvania and also holds a Master's degree in Translational Research from the University of Pennsylvania. His clinical and research interests focus on bleeding and clotting disorders, including hemophilia, thrombosis, immune thrombocytopenia (ITP), and heparin-induced thrombocytopenia (HIT). He has been involved in numerous studies and clinical trials aimed at improving the diagnosis and treatment of these conditions. Adam Cuker, MD has published extensively in peer-reviewed journals and contributed to the development of new therapeutic strategies in hematology. In addition to his research, Adam Cuker, MD is deeply committed to medical education. He has received several accolades for teaching and mentorship, reflecting his dedication to training the next generation of hematologists. Through his combined efforts in clinical care, research, and education, Adam Cuker, MD continues to advance the understanding and management of complex coagulation and bleeding disorders.